Orthostatic Intolerance in EDS
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Orthostatic Intolerance V1 4.2.11, F10 Overview V2 6036-7,7038,7040,7042 Orthostatic Intolerance
NASA-STD-3001 Technical Brief Orthostatic Intolerance V1 4.2.11, F10 Overview V2 6036-7,7038,7040,7042 Orthostatic Intolerance Executive Summary Orthostatic intolerance (OI) is an abnormal response to standing upright caused by an inability to maintain arterial blood pressure and perfuse cerebral tissue. It can result in presyncope and, ultimately, syncope (i.e. loss of consciousness). Specifically in the spaceflight community, OI is a major concern when crewmembers are re-introduced to gravity after landing due to decreased plasma volume and sympathetic nervous system dysfunction. OI must also be considered for standing crew experiencing acceleration loads. A variety of countermeasures can be implemented to reduce the symptoms of and/or completely mitigate OI. Standards Overview NASA-STD-3001 Vol. 1 4.2.11 Fitness-for-Duty Orthostatic Hypotension Standard (with Appendix F.10) All approved countermeasures (fluid loading and compression garments) shall be utilized to mitigate symptoms of orthostatic hypotension (presyncopal/syncopal symptoms) to prevent impacts to performance of critical mission tasks. NASA-STD-3001 Vol. 2 6.3.2.8 Fluid Loading Water Quantity for Earth Entry [V2 6036] 6.3.2.9 Crew recovery Water Quantity [V2 6037] 7.4.1 Physiological Countermeasures Capability [V2 7038] The system shall provide countermeasures to meet crew bone, muscle, sensory-motor, and cardiovascular requirements defined in NASA-STD-3001, Vol. 1. 7.4.3 Physiological Countermeasure Operations [V2 7040] The physiological countermeasure system design shall allow the crew to unstow supplies, perform operations, and stow items within the allotted countermeasure schedule. 7.4.5 Orthostatic Intolerance Countermeasures [V2 7042] The system shall provide countermeasures to mitigate the effects of orthostatic intolerance when transitioning from microgravity to gravity environments. -
Review of Systems Form
Child’s name or label Since the last visit, how are your child’s symptoms? Better? Worse? The same? Please describe: Any new health problems, consultations, ER visits, hospital admissions, procedures or surgeries since your last visit? None Evaluations or tests done since the last visit: MRI EEG Blood work Child Study Team evaluation Neuropsychological testing ImPACT test Audiology Nutritionist consultation Questionnaires Physician Consultations:______________________ Other: ____________________ None If your child takes medications, please list the medications and doses here: 1.__________________________________________________ 4.__________________________________________ 2._________________________________________________ 5._________________________________________ 3.__________________________________________________ 6.__________________________________________ PEDS NEURO REVIEW OF SYSTEMS: Please list symptoms your child has since the last visit. Describe “yes” responses. NEUROLOGICAL KNOWN EYE CONDITIONS YES NO ___________________ HYPERACTIVITY YES NO ___________________ EAR, NOSE AND THROAT SEIZURES YES NO ___________________ HEARING LOSS OR DEFICIT YES NO ___________________ FAINTING YES NO ___________________ SLEEP APNEA YES NO ___________________ SNORING YES NO ___________________ CARDIOVASCULAR HEADACHES YES NO ___________________ RAPID OR IRREGULAR HEART BEAT YES NO ___________________ TICS YES NO ___________________ CHEST PAIN OR EXERCISE INTOLERANCE YES NO ___________________ INATTENTION -
NIH Public Access Author Manuscript Auton Neurosci
NIH Public Access Author Manuscript Auton Neurosci. Author manuscript; available in PMC 2016 March 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Auton Neurosci. 2015 March ; 188: 86–89. doi:10.1016/j.autneu.2014.11.008. Exercise in the Postural Orthostatic Tachycardia Syndrome Qi Fu and Benjamin D. Levine Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, The University of Texas Southwestern Medical Center, Dallas, TX, USA Abstract Patients with the Postural Orthostatic Tachycardia Syndrome (POTS) have orthostatic intolerance, as well as exercise intolerance. Peak oxygen uptake (VO2peak) is generally lower in these patients compared with healthy sedentary individuals, suggesting a lower physical fitness level. During acute exercise, POTS patients have an excessive increase in heart rate and reduced stroke volume for each level of absolute workload; however, when expressed at relative workload (%VO2peak), there is no difference in the heart rate response between patients and healthy individuals. The relationship between cardiac output and VO2 is similar between POTS patients and healthy individuals. Short-term (i.e., 3 months) exercise training increases cardiac size and mass, blood volume, and VO2peak in POTS patients. Exercise performance is improved after training. Specifically, stroke volume is greater and heart rate is lower at any given VO2 during exercise after training versus before training. Peak heart rate is the same but peak stroke volume and cardiac output are greater after training. Heart rate recovery from peak exercise is significantly faster after training, indicating an improvement in autonomic circulatory control. These results suggest that patients with POTS have no intrinsic abnormality of heart rate regulation during exercise. -
Pulmonary Hypertension and Exercise Intolerance in Patients with Heart Failure Javed Butler, MD, Don B
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 34, No. 6, 1999 © 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00408-8 Pulmonary Hypertension and Exercise Intolerance in Patients With Heart Failure Javed Butler, MD, Don B. Chomsky, MD, John R. Wilson, MD, FACC Nashville, Tennessee OBJECTIVES This study was undertaken to investigate the relationship between pulmonary hypertension and exercise performance in patients with heart failure. BACKGROUND The exercise capacity of patients with heart failure is frequently reduced. Pulmonary hypertension may contribute to this exercise intolerance by impairing blood flow through the pulmonary circulation. METHOD Three hundred twenty patients with heart failure underwent upright treadmill exercise testing with hemodynamic monitoring. The incidence of pulmonary hypertension and the relation- ship between pulmonary vascular resistance (PVR) and exercise cardiac output and minute oxygen consumption (VO2) were examined. RESULTS Pulmonary vascular resistance was normal (Ͻ1.5 Wood Units; Group 1) in 28% of the patients, mildly elevated (1.5 to 2.49 Wood Units; Group 2) in 36%, moderately elevated (2.5 to 3.49 Wood Units; Group 3) in 17% and severely elevated (Ͼ3.5 Wood Units; Group 4) in 19%. Increasing PVR was associated with significantly lower peak exercise VO2 (Group 1: 13.9 Ϯ 3.7; 2:13.7 Ϯ 3.4; 3: 11.8 Ϯ 2.4; 4: 11.5 Ϯ 2.6 L/min, p Ͻ 0.01 Groups 3 and 4 vs. -
Impact of Atrial Fibrillation on Exercise Capacity And
ORIGINAL RESEARCH Impact of Atrial Fibrillation on Exercise Capacity and Mortality in Heart Failure With Preserved Ejection Fraction: Insights From Cardiopulmonary Stress Testing Mohamed B. Elshazly, MD; Todd Senn, MD; Yuping Wu, PhD; Bruce Lindsay, MD; Walid Saliba, MD; Oussama Wazni, MD; Leslie Cho, MD Background-—Atrial fibrillation (AF) has been objectively associated with exercise intolerance in patients with heart failure with reduced ejection fraction; however, its impact in patients with heart failure with preserved ejection fraction has not been fully scrutinized. Methods and Results-—We identified 1744 patients with heart failure and ejection fraction ≥50% referred for cardiopulmonary stress testing at the Cleveland Clinic (Cleveland, OH), 239 of whom had AF. We used inverse probability of treatment weighting to balance clinical characteristics between patients with and without AF. A weighted linear regression model, adjusted for unbalanced variables (age, sex, diagnosis, hypertension, and b-blocker use), was used to compare metabolic stress parameters and 8-year total mortality (social security index) between both groups. Weighted mean ejection fraction was 58Æ5.9% in the entire population. After adjusting for unbalanced weighted variables, patients with AF versus those without AF had lower mean peak oxygen consumption (18.5Æ6.2 versus 20.3Æ7.1 mL/kg per minute), oxygen pulse (12.4Æ4.3 versus 12.9Æ4.7 mL/beat), and circulatory power (2877Æ1402 versus 3351Æ1788 mm HgÁmL/kg per minute) (P<0.001 for all comparisons) but similar submaximal exercise capacity (oxygen consumption at anaerobic threshold, 12.0Æ5.1 versus 12.4Æ6.0mL/kg per minute; P =0.3). Both groups had similar peak heart rate, whereas mean peak systolic blood pressure was lower in the AF group (150Æ35 versus 160Æ51 mm Hg; P<0.001). -
Neurocardiogenic Syncope and Associated Conditions: Insight Into Autonomic Nervous System Dysfunction
Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2013;41(1):75-83 doi: 10.5543/tkda.2013.44420 75 Neurocardiogenic syncope and associated conditions: insight into autonomic nervous system dysfunction Nörokardiyojenik senkop ve ilişkili durumlar: Otonomik sinir sistemi işlev bozukluğuna bir bakış Antoine Kossaify, M.D., Kamal Kallab, M.D. Department of Syncope and Electrophysiology, ND Secours/USEK University Hospital, Byblos, Lebanon Summary– Neurocardiogenic syncope is known to be asso- Özet– Nörokardiyojenik senkopun mekanizması hala tam ola- ciated with autonomic nervous system dysfunction, although rak aydınlatılamamasına ragmen otonom sinir sistemi işlev the mechanism has not been entirely elucidated. In this study, bozukluğu ile ilişkili olduğu bilinmektedir. Bu yazıda nörokardi- we sought to highlight the pathogenic role of the autonomic yojenik senkop patogenezinde otonom sinir sisteminin rolünü nervous system in neurocardiogenic syncope and to review destekleyen en göze çarpıcı konuları araştırırken, temelinde the associated co-morbidities known to have a dysautonomic otonom sinir sistemi bozukluğunun olduğu bilinen komorbid basis. Herein we discuss migraine, orthostatic hypotension, durumları da gözden geçidik. Bu amaçla otonom sinir siste- postural orthostatic tachycardia syndrome, endothelial dys- minin patogenezdeki rolü ve klinik çıkarımları üzerine odak- function, chronic fatigue syndrome, and carotid sinus hyper- lanarak migren, ortostatik hipotansiyon, postüral ortostatik sensitivity with a focus on the pathogenic role of the autonom- taşikardi sendromu, endotel işlev bozukluğu, kronik yorgunluk ic nervous system and any consecutive clinical implications. sendromu ve karotis sinüs hipersensitivitesi tartışıldı. Tilt testi Other conditions, such as pre-syncopal heart rate acceleration sırasında ortaya çıkabilen senkop öncesi kalp atımlarında hız- and/or instability and pre-syncopal breathing instability, which lanma ve/veya instabilite ve senkop öncesi instabil solunum occur during a tilt test, are discussed in the same perspective. -
Statewide Heart Failure Service, Heart Failure Daily Diary
Available online at www.sciencedirect.com Journal of Science and Medicine in Sport 13 (2010) 288–294 Position statement Exercise & Sports Science Australia Position Statement on exercise training and chronic heart failure Steve E. Selig a,b,∗, Itamar Levinger a,b, Andrew D. Williams c, Neil Smart d, David J. Holland e, Andrew Maiorana f,g, Daniel J. Green h,i, David L. Hare b,j a Institute for Sport, Exercise and Active Living, School of Sport and Exercise Science, Victoria University, Melbourne, Australia b Department of Cardiology, Austin Health, Melbourne, Australia c School of Human Life Sciences, University of Tasmania, Tasmania, Australia d Faculty of Health Science and Medicine, Bond University, QLD, Australia e School of Medicine, University of Queensland, Brisbane, Australia f Cardiac Transplant Unit, Royal Perth Hospital, Australia g School of Physiotherapy, Curtin University of Technology, Australia h School of Sport Science, Exercise and Health, University of Western Australia, Australia i Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, United Kingdom j School of Medicine, University of Melbourne, Australia Received 18 September 2009; received in revised form 18 January 2010; accepted 19 January 2010 Abstract Chronic heart failure (CHF) is a complex syndrome characterised by progressive decline in left ventricular function, low exercise tolerance and raised mortality and morbidity. Regular exercise participation has been shown to be a safe and effective treatment modality in the majority of CHF patients, partially reversing some of the maladaptations evident in myocardial and skeletal muscle function, and resulting in improvements in physical fitness and quality of life, and perhaps reduced mortality. -
Ehlers-Danlos Syndrome and the Overlap with Orthostatic Intolerance
10/9/2014 Ehlers‐Danlos Syndrome Ehlers‐Danlos Syndrome and the Overlap with Orthostatic Intolerance • Heterogeneous disorder of connective tissue • Characterized by varying degrees of: October 9, 2014 Skin hyperextensibility Joint hypermobility Cutaneous fragility Peter C. Rowe, MD •Most forms of EDS result from mutations in genes Sunshine Natural Wellbeing Foundation Professor of encoding fibrillar collagens or the collagen‐ Chronic Fatigue and Related Disorders modifying enzymes Johns Hopkins University School of Medicine 1. Royce PM, Steinmann B, Superti‐Furga A. The Ehlers‐Danlos syndrome. In: Connective Tissue and its Heritable Baltimore, USA Disorders. New York: Wiley‐Liss, 1993: 351‐407. 2. de Paepe A, Malfait F. The Ehlers‐Danlos syndrome, a disorder with many faces. Clin Genetics 2012;82:1‐11. Presenter Disclosure Information Ehlers‐Danlos Syndrome Peter C. Rowe, MD • Prevalence unknown, estimated at 1:5000 •Because fibrillar collagen provides strength and structure to essentially all tissues and organs, EDS •No relationships to disclose has widespread clinical manifestations •Early varicose veins, easy bruising •Easy fatigability and widespread pain common Royce PM, Steinmann B, Superti‐Furga A. The Ehlers‐Danlos syndrome. In: Connective Tissue and its Heritable Disorders. New York: Wiley‐Liss, 1993: 351‐407. EDS, JH, and Orthostatic Intolerance Classification of EDS Beighton P, et al. Am J Med Genetics 1998;77:31‐7. Overview of Ehlers‐Danlos Syndrome Classical Illustrative case (formerly EDS I and II) Orthostatic intolerance in EDS and JH Hypermobility (formerly EDS III) Challenges Vascular (formerly EDS IV) Kyphoscoliosis Arthrochalasia 3 generations with Classical EDS. Note hemosiderin deposition in knees and Dermatosparaxis shins, varicose vein stripping on R 1 10/9/2014 de Paepe A, Malfait F. -
GP GUIDE to Pots (Postural Tachycardia Syndrome)
GP GUIDE TO PoTS (Postural Tachycardia Syndrome) 1 WHAT IS PoTS? PoTS was characterised in 1993, but previously existed under various other names including irritable heart, soldier’s heart and idiopathic orthostatic intolerance. It is a heterogeneous group of disorders sharing similar characteristics. On assuming upright posture, there is an excessive increase in heart rate associated with symptoms of orthostatic intolerance and sympathetic over-activity. There is brain hypoperfusion, usually in the absence of hypotension. When humans adopt upright posture, approximately 500ml of blood drops into the abdominal cavity and limbs. A normal autonomic nervous system responds with immediate peripheral vasoconstriction and an increase in heart rate of up to 20bpm. In POTS, it is considered that vasoconstriction is inadequate, resulting in pooling of blood, relative hypovolaemia and reduced venous return to the heart. Heart rate, inotropic status and, in some patients, catecholamine levels increase further to compensate. Dizziness and syncope can occur in the presence of normal BP; in fact some patients with PoTS have a hypertensive response to standing. HOW COMMON IS PoTS? The incidence in the UK is unknown. However, it is probably under-diagnosed due to lack of awareness and non-specific symptomatology. It is five times more common in women and tends to affect people age 15 to 50. 2 SYMPTOMS OF PoTS Dizziness GI upset Syncope / pre-syncope Sweating Orthostatic headache Nausea Fatigue Insomnia Poor memory Weakness Poor concentration Visual greying or blurring Sense of anxiety Acrocyanosis (purplish hands/feet) Exercise intolerance Palpitations (tachycardia / ectopics) Tremulousness Neck/shoulder pain (muscle ischaemia) Patients may have some or all of the above symptoms. -
What Is the Autonomic Nervous System?
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.suppl_3.iii31 on 21 August 2003. Downloaded from AUTONOMIC DISEASES: CLINICAL FEATURES AND LABORATORY EVALUATION *iii31 Christopher J Mathias J Neurol Neurosurg Psychiatry 2003;74(Suppl III):iii31–iii41 he autonomic nervous system has a craniosacral parasympathetic and a thoracolumbar sym- pathetic pathway (fig 1) and supplies every organ in the body. It influences localised organ Tfunction and also integrated processes that control vital functions such as arterial blood pres- sure and body temperature. There are specific neurotransmitters in each system that influence ganglionic and post-ganglionic function (fig 2). The symptoms and signs of autonomic disease cover a wide spectrum (table 1) that vary depending upon the aetiology (tables 2 and 3). In some they are localised (table 4). Autonomic dis- ease can result in underactivity or overactivity. Sympathetic adrenergic failure causes orthostatic (postural) hypotension and in the male ejaculatory failure, while sympathetic cholinergic failure results in anhidrosis; parasympathetic failure causes dilated pupils, a fixed heart rate, a sluggish urinary bladder, an atonic large bowel and, in the male, erectile failure. With autonomic hyperac- tivity, the reverse occurs. In some disorders, particularly in neurally mediated syncope, there may be a combination of effects, with bradycardia caused by parasympathetic activity and hypotension resulting from withdrawal of sympathetic activity. The history is of particular importance in the consideration and recognition of autonomic disease, and in separating dysfunction that may result from non-autonomic disorders. CLINICAL FEATURES c copyright. General aspects Autonomic disease may present at any age group; at birth in familial dysautonomia (Riley-Day syndrome), in teenage years in vasovagal syncope, and between the ages of 30–50 years in familial amyloid polyneuropathy (FAP). -
Review of Systems Health History Sheet Patient: ______DOB: ______Age: ______Gender: M / F
603 28 1/4 Road Grand Junction, CO 81506 (970) 263-2600 Review of Systems Health History Sheet Patient: _________________ DOB: ____________ Age: ______ Gender: M / F Please mark any symptoms you are experiencing that are related to your complaint today: Allergic/ Immunologic Ears/Nose/Mouth/Throat Genitourinary Men Only Frequent Sneezing Bleeding Gums Pain with Urinating Pain/Lump in Testicle Hives Difficulty Hearing Blood in Urine Penile Itching, Itching Dizziness Difficulty Urinating Burning or Discharge Runny Nose Dry Mouth Incomplete Emptying Problems Stopping or Sinus Pressure Ear Pain Urinary Frequency Starting Urine Stream Cardiovascular Frequent Infections Loss of Urinary Control Waking to Urinate at Chest Pressure/Pain Frequent Nosebleeds Hematologic / Lymphatic Night Chest Pain on Exertion Hoarseness Easy Bruising / Bleeding Sexual Problems / Irregular Heart Beats Mouth Breathing Swollen Glands Concerns Lightheaded Mouth Ulcers Integumentary (Skin) History of Sexually Swelling (Edema) Nose/Sinus Problems Changes in Moles Transmitted Diseases Shortness of Breath Ringing in Ears Dry Skin Women Only When Lying Down Endocrine Eczema Bleeding Between Shortness of Breath Increased Thirst / Growth / Lesions Periods When Walking Urination Itching Heavy Periods Constitutional Heat/Cold Intolerance Jaundice (Yellow Extreme Menstrual Pain Exercise Intolerance Gastrointestinal Skin or Eyes) Vaginal Itching, Fatigue Abdominal Pain Rash Burning or Discharge Fever Black / Tarry Stool Respiratory Waking to Urinate at Weight Gain (___lbs) Blood -
Pathophysiology of Exercise Intolerance in Chronic Diseases: the Role of Diminished Cardiac Performance in Mitochondrial and Heart Failure Patients
Open Access Heart failure and cardiomyopathies Open Heart: first published as 10.1136/openhrt-2017-000632 on 28 July 2017. Downloaded from Pathophysiology of exercise intolerance in chronic diseases: the role of diminished cardiac performance in mitochondrial and heart failure patients Jodi McCoy,1 Matthew Bates,1,2 Christopher Eggett,1 Mario Siervo,1 Sophie Cassidy,1 Jane Newman,1 Sarah A Moore,3 Grainne Gorman,3,4 Michael I Trenell,1,5 Lazar Velicki,6 Petar M Seferovic,7 John G F Cleland,8 Guy A MacGowan,9 Doug M Turnbull,3,4 Djordje G Jakovljevic1,10 To cite: McCoy J, Bates M, ABSTRACT KEY QUESTIONS Eggett C, et al. Pathophysiology Objective Exercise intolerance is a clinical hallmark of exercise intolerance in of chronic conditions. The present study determined chronic diseases: the role of What is already known about this subject? pathophysiological mechanisms of exercise intolerance in diminished cardiac performance Exercise intolerance is a clinical hallmark of cardiovascular, neuromuscular, and metabolic disorders. ► in mitochondrial and heart chronic conditions and strong predictor of Methods In a prospective cross-sectional observational failure patients. Open Heart morbidity and mortality. 2017;4:e000632. doi:10.1136/ study 152 patients (heart failure reduced ejection openhrt-2017-000632 fraction, n=32; stroke, n=34; mitochondrial disease, What does this study add? n=28; type two diabetes, n=28; and healthy controls, ► The study highlights that pathophysiological n=30) performed cardiopulmonary exercise testing with mechanisms of exercise intolerance differ among Received 22 March 2017 metabolic and haemodynamic measurements. Peak patients groups. Revised 22 May 2017 exercise O consumption and cardiac power output were Accepted 20 June 2017 2 measures of exercise tolerance and cardiac performance.